In order to identify the proteomic differences between renal cell carcinoma (RCC) and benign renal tumors, we analyzed 168 serum samples from 65 RCC patients, 34 patients with benign renal tumors, and 69 healthy persons using the IMAC-Cu2+ ProteinChip system by surface enhanced laser desorption/ionization mass spectrometry technology. Two decision trees were generated by Biomarker Pattern software to distinguish between RCC versus healthy and RCC versus patients with benign tumors, respectively. Although the sensitivity and specificity of the RCC vs. healthy decision tree were 97.6% and 95.7%, respectively, it could not be used to distinguish RCC from benign renal tumors. The sensitivity of a blind test process using RCC, benign tumors and healthy persons were 92%. The specificity of the test process was 35.3% for benign tumors and 95.5% for healthy persons. The sensitivity and specificity of the RCC-Benign tumors decision tree were 85.7% and 95.5%, respectively. The blind test process using RCC, benign tumors and healthy persons also showed significant results. The sensitivity was 90.0%. The specificity was 95.7% for healthy persons and 90.0% for benign tumors. Combining these data with the results of CT scanning, the sensitivity can be improved over the use of either CT and decision tree analysis and the specificity may reach 100%. Two peaks with molecular masses of 3887.11 Da and 11079.8 Da were detected that are potentially useful for the diagnosis or screening of RCC. It was found that these two peaks can be used, not only to distinguish the RCC vs. healthy cases, but also to distinguish RCC from benign renal tumors. In combination with CT scanning, the sensitivity and specificity of the diagnosis of renal tumors can be improved. However, the decision tree constructed for RCC and healthy persons may not present good specificity for use in distinguishing malignant from benign renal tumors.
are not cost-effective because of the relatively low incidence of RCC. Furthermore, diagnostic radiography has been estimated to contribute to the cumulative risk of cancer (4). Therefore, new efficient and safe methods for RCC screening other than radiographic evaluation are clearly needed.
Proteomics has presented a new avenue for biomarker discovery. The surface enhanced laser desorption/ionization-time of flight-mass spectrometry technology (SELDI-TOF-MS) is the key technology, and has been reported to be highly successful for the diagnosis of various cancers, including ovary (5) , breast (6), prostate (7), and colorectal cancer (8) .
Several studies (9-11) have detected potential serum biomarkers for RCC by using the ProteinChip system based on SEL-DI-TOF-MS technology. Results of these studies have a high sensitivity and specificity (ranging from 80% to near 100%) to distinguish RCC patients from healthy persons or patients with other urologic diseases. The objective of this study is to find biomarkers that can be used to distinguish RCC from healthy persons and also from patients with benign renal tumors. Using this approach of proteomic screening of serum, we identified two molecules with molecular masses of 3887.11 Da and 11079.8 Da that can distinguish RCC patients from both healthy persons and patients with benign renal tumors.
Methods

Patients and Serum Samples
Blood samples were collected from 168 individuals, including 65 patients with RCC (55.2 ± 10.1 years of age), 34 patients with benign renal tumors (49.5 ± 11.7 years of age), and 69 healthy volunteers (54.9 ± 10.4 years of age). The age of the patients in the three groups was not significantly different (P>0.05, t test). All the 99 patients underwent surgery in the Urology Department of Hua Shan Hospital, Fu Dan University between October 2005 and April 2007. All patients have been diagnosed by computerized tomography (CT) before surgery and diagnosis was pathologically confirmed. All 65 RCC tumors were of the clear cell carcinoma type, including 47 cases of Robson stage I, seven cases of stage II, seven cases of stage IIIa, two cases of IIIb, and two cases of IVb. Thirty out of the 65 RCC patients were small RCC (tumor size ≤ 3 cm in diameter). The 34 patients with benign renal tumors were diagnosed with renal angioleiomyolipoma (10 patients), cysts (18 patients), adenoma (two patients), inflammatory pseudotumor (two patients), and fibroma (two patients). Samples from healthy volunteers were provided by the Shanghai municipal Centre for Disease Control and Prevention (SCDC) serum sample bank. Informed consent was obtained from all of the donors and the study was approved by the ethical committees. The blood samples were collected in the morning from patients with empty stomachs (2-3days before the surgery for the patients). Five milliliter blood samples were collected and centrifuged one hour later at 4000 rpm at 4 ºC for 5 min, and about 1-2 ml of serum were collected. The sera were then aliquotted into Eppendoff tubes and stored at -80 ºC.
All the patients had been diagnosed by enhanced CT scan before surgery. The model of the CT was GE lightspeed™ and the contrast medium was Omnipaque™ from GE Healthcare company.
ProteinChip Array
Three different kinds of chips (SAX2, H4, IMAC-Cu 2+ ) were evaluated to investigate which gave the best serum profile. IMAC-Cu 2+ was found to allow detection of the most peaks. The procedure was as follows. (I) 10 μl of 200 mmol/L CuSO 4 was applied to each spot of the chip for 10 minutes. This was done twice. After each spot was washed three times with 10 μl deionized water, 10 μl of 50 mM NaAC (pH3.0) was applied to the spots for 3 min. Spots were then washed three times with deionized water. (II) 200 μl binding buffer (PBS pH7.2 with 500 mM NaCl) was applied to each spot. This was performed twice. (III) The serum samples were thawed at 4 ºC. After centrifugation at 10000 rpm (four minutes, 4 ºC), each serum was diluted 1:40 in binding buffer. Afterwards, 200 μl diluted serum was applied to each spot and samples were then put on the shaker for 1.5 hours. (IV) After the samples were removed, 200 μl binding buffer was applied to each spot for an additional incubation on the shaker for five minutes. This was performed twice. After this, each spot was washed with 300 μl of deionized water for one minute. (V) The spots were air-dried, and soon thereafter, matrix (50% sinapinic acid in 50% acetonitrile/0.1% trifluoroacetic acid) was added to the chips twice.
All arrays were read on a Protein Biological System IIc Pro-teinChip reader (Ciphergen Biosystems, Inc.). Spectra were collected with a laser intensity of 155 and a detector sensitivity of eight. The optimized range was set at 1000 Da~30000 Da.
Peak Detection
The spectrums were processed by Ciphergen ProteinChip software (ver. 3.0). All 168 acquired spectra were complied and analyzed as a whole. Cluster analysis of the detected signals and determination of respective p-values were carried out with the Biomarker Wizard Program (ver. 3.0). For p-value calculations, spectra with at least 10 signals in the range between 2 kDa and 20 kDa exhibiting a signal noise-to-ratio (S/N) of at least two were selected and analyzed with the Mann-Whitney U test for non-parametric data sets. The two peaks of 5907 Da and 8935 Da were used as normalizing peaks for all of the 168 spectra. The normalized factors of three RCC samples were higher than 2.5, which means the data quality of these 3 samples were not suitable for analysis. At the end, 62 cases of RCC, 34 cases of benign renal tumors and 69 healthy persons were analyzed. The coefficient of variance (CV) for the peak intensity was between 0.02 and 0.25.
Decision Tree
The decision tree classifies a spectrum pattern through a sequence of questions, in which the next question asked depends upon the answer to the previous question. The sequence of questions forms a node connected by successive links or branches downward to other nodes. The questions asked at each node concern a particular property of the spectrum patterns, such as 3887.11<=22.638, where the number on the left side indicates the Dalton-value of the molecule and the one on the right side indicates the peak intensity value. With the decision tree, classification of a particular pattern begins at the root node, and follows the appropriate link based on the answer to the question at each node. For example, a node in the tree asks the question, "Does peak at 3887.11 Da have a peak intensity smaller than or equal to 22.638?" If the answer is "yes", we follow the left link, otherwise, we go right. This process is repeated until a terminal node is reached.
At each node of the tree, the question concerns the property of the spectrum that makes the data at the descendent nodes as "pure" as possible. For this purpose, a cost function is computed that reflects the heterogeneity of each descendent node. The most popular measurement for the cost is the entropy impurity, which is defined as follows:
where P(w j ) is the fraction of the spectrum data at node N that is in class category w j . Thus, peaks selected by this method to form the classification rules are the ones that achieve maximum reduction of cost in the next descendent nodes.
Results
High Sensitivity and Low Specificity of a Decision-tree-baseddiscrimination Between RCC and Benign Renal Tumors
Forty-two randomly-chosen RCC patients and 47 healthy persons were used as the training set. The other 20 RCC patients, the 34 patients with benign renal masses, and the other 22 healthy persons were analyzed as the test set. The Biomarker Pattern software constructed a decision tree with five judging nodes and six terminal nodes using five distinct masses (8936.62 Da, 8607.53 Da, 4646.7 Da, 4093.25 Da, and 3895.72 Da) , as shown in Figure 1 . The sensitivity of this decision tree for the training set is 97.6% (41/42), and the specificity is 95.7% (45/47).
Subsequently, the test set was used to test the constructed decision tree. The sensitivity of the test process was 90.0% (18/20). The specificity was 35.3% (12/34) for benign tumors and 95.5% (21/22) for healthy persons. Twenty-two out of 34 patients of the patients with benign renal tumors (64.7%) were incorrectly determined to be RCC patients by the algorithms. Some peaks (e.g., 8936.62 Da), which could distinguish RCC from healthy persons, showed no difference in peak intensity between RCC and benign tumors, as shown in Figure 2 .
High Sensitivity and Specificity of a Decision Tree Constructed for Discrimination Between RCC Patients and Patients with Benign Renal Tumors
In this second part of the study, 42 randomly-chosen RCC patients and 22 patients with benign renal tumors were used as a training set and the other 20 RCC patients, 12 cases of benign tumors, and 69 healthy persons were reserved as the test group. The Biomarker Pattern software constructed a decision tree with three judging nodes and four terminal nodes using two distinct masses (3887.11Da and 11079.8Da), as shown in Figure 3 . The sensitivity of this decision tree was found to be 85.7% (36/42) and the specificity was 95.5% (21/22).
Then, the test set was used to test the decision tree. The algorithms correctly predicted 93.1% (94/101) of the test samples. The sensitivity of this test process was 90.0% (18/20). The specificity was 95.7% (66/69) for healthy persons and 83.3% (10/12) for benign tumors. The 3887.11 Da peak could not only distinguish RCC patients from patients with benign renal tumors, but could also distinguish RCC patients from healthy persons successfully (Fig. 4) . The peak intensity at 3887.11 Da of the large RCC, small RCC, benign tumors, and healthy persons were 29.71 ± 22.38, 49.00 ± 16.24, 14.27 ± 3.74, 14.22 ± 6.27, respectively.
Combining SELDI-TOF-MS Technology with CT Scan can Improve the Sensitivity and Specificity of Diagnosis
The sensitivity of CT scan was much higher than the specificity. In this study, 41.2% (14/34) of the patients with benign renal tumors were falsely diagnosed as RCC by CT scan. So we tried to combine diagnosis by CT analysis with the decision tree constructed for discrimination between RCC patients and patients with benign renal tumors using parallel test and serial test. The specificity of serial testing was 100% and the sensitivity of parallel tests was a found to be higher than that found by only CT scanning (Table I) .
Discussion
Although CT or other imaging technologies can easily detect renal tumors over 1 cm in diameter, certain small solid tumors (< or = 3-cm-diameter) cannot be diagnosed confi- dently with CT alone or with additional imaging tools such as MRI. In these cases, percutaneous biopsy or even surgery may be warranted (12). In the study of Remzi et al. (13) , malignancy suspect exists for 83% (67/80) of the patients in which a tumor mass was detected. Furthermore, 28 out of 67 (42%) had a radical nephrectomy for benign lesions not correctly identified as benign by the CT scan before surgery. In our study, 41.2% (14/34) of the patients with benign renal tumors that were candidates for malignancy according to the CT scan before surgery were finally confirmed as benign by pathological findings after surgery.
In the first part of this study, our proteomic decision-tree based approach easily separated RCC patients from healthy persons, confirming results presented in previous studies (9-11). However, we discovered that some peaks that could distinguish serum from RCC patients from healthyperson-derived-serum did not differentiate between RCC and benign tumors (Fig. 2) , which means that those peaks may not be related to RCC, but may be associated with renal tumors (both benign and malignant) or other renal diseases. This may explain why those patients with benign renal tumors were categorized as RCC in most cases (64.7%) by the first decision tree. The study from Hara et al. (11) presented an overall specificity of 80% of a blind test process, but the specificity was only 20% for patients with pyelonephritis. Tolson et al. (9) found two peaks with masses of 9200 Da and 11683 Da, which were further confirmed as haptoglobin 1-α and serum amyloid α-1. These two molecules belong to the 
Figure 2:
Protein spectra of sera of RCC and benign tumor patients and normal healthy controls. The peak intensity of 8936.62 Da is much higher in RCC than that in healthy persons, but there seems to be no significant deference between RCC and benign renal tumors. acute phase protein family that also exists in many patients with malignant tumors. Haptoglobin 1α can be found in ovarian cancer (14), while serum amyloid α-1 can be found in prostate cancer (15), ovarian cancer (16), and nasopharyngeal carcinoma (17) . It was argued that most peaks found by proteomic technologies were molecules associated with the "epiphenomena" of cancer, such as malnutrition, inflammatory cytokines, infection, or cachexia (18).
The sensitivity and specificity of the second decision tree is not as good as the first decision tree, but favorable results can be obtained when it is applied to distinguish RCC patients from healthy persons during the blind validation process. Combined with CT scanning the sensitivity and specificity can be improved. It may be suggested that this decision tree has more clinical value than the first tree because some peaks that are not different between cancer sera and sera of patients with benign tumors may have been eliminated. Indeed, our study eliminated organ-to-organ bias in comparisons of benign and malignant renal tumors, but cancerto-cancer bias may still remain.
There are different levels of intensity of the 3887.11 Da peak of RCC (>22.638 or <=9.405). Pahernik et al. (19) reported that prognostic features predicting short survival increase with renal tumor diameter, and that in tumors larger than 3.0 cm in diameter, a sharp increase in the incidence of these prognostic parameters is seen. Therefore, we stratified RCC patients into two subgroups by the size of the tumor. Eighty percent (12/15) of the small (<=3cm) RCC cases were in terminal node 4 (3887.11 Da>22.638) and only 40.7% (11/27) of the cases of the large tumor group were in this node. However, in terminal node 1 (3887.11 Da<=9.405), the small tumor group only contributed two cases of the total of nine cases. The other seven cases were all from the large tumor group. We also separated RCC patients by the Robson stage. In terminal node 4 (3887.11 Da>22.638), 82.6% (19/23) of the cases were in the group of stage I tumors, which also contributed 88.9% (8/9) of the cases in terminal node 1 (3887Da<=9.405). We finally compared this peak intensity of the small RCC and the large RCC group. The peak intensities of the small RCC and large RCC group was 49.00 ± 16.24 and 29.71 ± 22.38 (P<0.05), respectively. We presume that the 3887.11 Da molecule is more likely associated with the size of the tumor than the stage of the tumor. When the tumor is small (diameter <=3cm), the serum level of this molecule is markedly higher than normal, but when the tumor continues to grow larger, its serum level decrease significantly. Future studies should Figure 4 : Protein spectra of sera of RCC and benign tumor patients and normal healthy controls. The peak intensity of 3887.11 Da is much higher in sera from RCC patients than in sera from patients with benign renal tumors and healthy persons. further confirm this hypothesis.
Conclusions
Two molecules, with molecular masses of 3887.11 Da and 11079.8 Da, were detected by proteomic analysis of patient sera, and are potentially useful for the diagnosis and/or screening of RCC. The expression level of these two molecules can be used for (i) distinguishing RCC patients from healthy individuals, (ii) to identify malignant disease in patients with renal tumors, and (iii) to improve the sensitivity and specificity of discrimination diagnosis of renal tumors by combining with diagnosis by CT scanning. However, decision tree constructed for RCC and healthy persons may not present sufficient specificity when used to distinguish malignant from benign tumors. Although current results are promising, further refinement of the techniques is warranted. In addition, further research is needed to identify the nature and function of the two molecules. This study eliminated some of the bias, such as organ-to-organ, but cancerto-cancer bias may still remain.
